Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2080-2085

  Fritsch, K ^a   Kasenda, B ^a   Hader, C ^a   Nikkhah, G ^a   Prinz, M ^a   Haug, V ^a   Haug, S ^a   Ihorst, G ^a   Finke, J ^a   Illerhaus, G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Elderly; High dose MTX; Non Hodgkin lymphoma; PCNSL; Rituximab

Indexed keywords

CYTARABINE; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RITUXIMAB; THIOTEPA;

AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DIVERTICULITIS; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LEUKOCYTE COUNT; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOMUSTINE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; PILOT PROJECTS; PROCARBAZINE; SURVIVAL ANALYSIS;

EID: 80052392027     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq712     Document Type: Article

References (23)

1. Panageas KS, Elkin EB, DeAngelis LM et al. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005; 104: 2466-2472.
2. Ferreri AJ, Reni M, Foppoli M et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-1520.
3. Colombat P, Lemevel A, Bertrand P et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417-420.
4. Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865-3870.
5. Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345: 425-432.
6. Gavrilovic IT, Hormigo A, Yahalom J et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570-4574.
7. Omuro AM, Taillandier L, Chinot O et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85: 207-211.
8. Zhu JJ, Gerstner ER, Engler DA et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11: 211-215.
9. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726-2731.
10. Illerhaus G, Marks R, Muller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20: 319-325.
11. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.
12. Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711-5715.
13. Illerhaus G, Muller F, Feuerhake F et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147-148.
14. Harjunpaa A, Wiklund T, Collan J et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42: 731-738.
15. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129-133.
16. Wong ET, Tishler R, Barron L et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101: 139-145.
17. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000; 11: 374-375.
18. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735.
19. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-3150.
20. Panageas KS, Elkin EB, Ben-Porat L et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007; 110: 1338-1344.
21. Jahnke K, Korfel A, Martus P et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005; 16: 445-449.
22. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-863.
23. Maria Ferreri AJ, Verona C, Politi LS et al. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 2010; in press